VORTEX BIOTECH HOLDINGS ANNOUNCES HIGH PROFILE APPOINTMENT
Nigel Brooksby appointed as Non-Executive Chairman
London, 28 January 2025. Vortex Biotech Holdings, (‘Vortex’, or ‘the Company’), a leading oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as Non-Executive Chairman.
Nigel is an experienced industry leader with extensive experience chairing and directing public and private companies. His career includes leadership roles in the pharmaceutical and biotechnology industries. Notably, he was Chairman and CEO of Sanofi UK, where he helped build the company into one of the top 10 pharmaceutical business globally. Nigel has also held senior positions at GSK and Pfizer International USA. His deep understanding of the financial, operational, and strategic aspects of the life sciences and pharmaceutical sectors, combined with his exceptional global network, will be invaluable as Vortex enters its next phase of growth.
Nigel Brooksby, incoming Non-Executive Chairman of Vortex, commented, “Vortex has a bright future ahead and I am looking forward to contributing to its success. The Company is at the cutting edge of delivering a step-change solution in cancer care. Liquid biopsy technologies utilising circulating tumour cells have the potential to revolutionise how we diagnose and treat cancer, offering the promise of more personalised therapies. I look forward to working alongside the team to continue advancing this critical technology and improving patient outcomes.”
Vortex’s Managing Director Paul Reeves, said, “Nigel’s appointment is a significant development for Vortex. His expertise in guiding companies from innovation to commercialisation in complex international markets positions us for rapid growth. We are entering a key phase of the business, as we look to build commercial traction for our liquid biopsy offering. With our base at the London Cancer Hub next to the Royal Marsden Hospital, we are ideally situated to lead the field of CTC capture technology and revolutionise therapeutic decision-making.”
A key benefit of Vortex’s liquid biopsy platform is that it provides results equivalent to more invasive diagnostic tools, but with the significant advantage of being less invasive and more patient-friendly. By using a blood sample, the liquid biopsy method eliminates the need for more cumbersome and invasive tissue biopsies, ultimately improving the patient experience and comfort. This less intrusive approach has the potential to make cancer diagnosis and monitoring more accessible, faster and less stressful for patients, while still delivering high-accuracy results for clinicians.
Nigel Brooksby is taking over from Dr. Ilian Iliev, CEO of EMV Capital PLC who was Chair during the Company’s period of development as part of EMV Capital’s Venture Building programme. He noted: “Nigel has extensive market knowledge and commercial expertise and I’d like to warmly welcome him to the Board. I believe that with these critical appointments in place, Vortex is positioned for significant growth. The Company’s advanced technology, combined with its world-class leadership team, is set to advance precision medicine and ultimately improve cancer care.”
